The Implications of the Generics UK ‘Pay-for-Delay’ Ruling of the Court of Justice of the European Union.  (C-307/18 Generics UK Ltd and Others v Competition and Market Authority of the 30th January 2020.)

FRANCO RIZZUTO; MONIKA LYNCH

doi:10.21552/core/2020/2/15

The Implications of the Generics UK ‘Pay-for-Delay’ Ruling of the Court of Justice of the European Union. (C-307/18 Generics UK Ltd and Others v Competition and Market Authority of the 30th January 2020.)

FRANCO RIZZUTO, MONIKA LYNCH

Research output: Contribution to journal › Article (journal) › peer-review

84 Downloads (Pure)

Abstract

On 20 January 2020, the Court of Justice of the European Union (CJEU) handed down its ruling in Case C-307/18 Generics (UK) and Others on ten complex questions referred by the UK Competition Appeal Tribunal (CAT) in the context of an appeal against a decision of the UK Competition and Markets Authority (CMA). In what will probably come to be regarded as a landmark judgment in EU competition law, the CJEU ruled for the first time on settlement agreements between originator pharmaceutical companies and producers of generic medicines

Original language	English
Pages (from-to)	150-163
Number of pages	14
Journal	European Competition and Regulatory Law Review
Volume	4
Issue number	2
Early online date	31 May 2020
DOIs	https://doi.org/10.21552/core/2020/2/15
Publication status	Published - 2020

Keywords

European Union
EU Competition Law

Access to Document

10.21552/core/2020/2/15

C 304-18 GENERICS (UK) Article final DV amended (1)Accepted author manuscript, 62.2 KB

Fingerprint

Dive into the research topics of 'The Implications of the Generics UK ‘Pay-for-Delay’ Ruling of the Court of Justice of the European Union. (C-307/18 Generics UK Ltd and Others v Competition and Market Authority of the 30th January 2020.)'. Together they form a unique fingerprint.

Cite this

@article{3bd015c199cf4d4383376d0b0d5b1293,

title = "The Implications of the Generics UK {\textquoteleft}Pay-for-Delay{\textquoteright} Ruling of the Court of Justice of the European Union. (C-307/18 Generics UK Ltd and Others v Competition and Market Authority of the 30th January 2020.)",

abstract = "On 20 January 2020, the Court of Justice of the European Union (CJEU) handed down its ruling in Case C-307/18 Generics (UK) and Others on ten complex questions referred by the UK Competition Appeal Tribunal (CAT) in the context of an appeal against a decision of the UK Competition and Markets Authority (CMA). In what will probably come to be regarded as a landmark judgment in EU competition law, the CJEU ruled for the first time on settlement agreements between originator pharmaceutical companies and producers of generic medicines",

keywords = "European Union, EU Competition Law",

author = "FRANCO RIZZUTO and MONIKA LYNCH",

year = "2020",

doi = "10.21552/core/2020/2/15",

language = "English",

volume = "4",

pages = "150--163",

journal = "European Competition and Regulatory Law Review",

issn = "2510-3148",

publisher = "Lexxion Verlagsgesellschaft mbH",

number = "2",

}

The Implications of the Generics UK ‘Pay-for-Delay’ Ruling of the Court of Justice of the European Union. (C-307/18 Generics UK Ltd and Others v Competition and Market Authority of the 30th January 2020.). / RIZZUTO, FRANCO; LYNCH, MONIKA.
In: European Competition and Regulatory Law Review, Vol. 4, No. 2, 2020, p. 150-163.

Research output: Contribution to journal › Article (journal) › peer-review

TY - JOUR

T1 - The Implications of the Generics UK ‘Pay-for-Delay’ Ruling of the Court of Justice of the European Union. (C-307/18 Generics UK Ltd and Others v Competition and Market Authority of the 30th January 2020.)

AU - RIZZUTO, FRANCO

AU - LYNCH, MONIKA

PY - 2020

Y1 - 2020

N2 - On 20 January 2020, the Court of Justice of the European Union (CJEU) handed down its ruling in Case C-307/18 Generics (UK) and Others on ten complex questions referred by the UK Competition Appeal Tribunal (CAT) in the context of an appeal against a decision of the UK Competition and Markets Authority (CMA). In what will probably come to be regarded as a landmark judgment in EU competition law, the CJEU ruled for the first time on settlement agreements between originator pharmaceutical companies and producers of generic medicines

AB - On 20 January 2020, the Court of Justice of the European Union (CJEU) handed down its ruling in Case C-307/18 Generics (UK) and Others on ten complex questions referred by the UK Competition Appeal Tribunal (CAT) in the context of an appeal against a decision of the UK Competition and Markets Authority (CMA). In what will probably come to be regarded as a landmark judgment in EU competition law, the CJEU ruled for the first time on settlement agreements between originator pharmaceutical companies and producers of generic medicines

KW - European Union

KW - EU Competition Law

UR - http://www.scopus.com/inward/record.url?scp=85098144030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098144030&partnerID=8YFLogxK

U2 - 10.21552/core/2020/2/15

DO - 10.21552/core/2020/2/15

M3 - Article (journal)

SN - 2510-3148

VL - 4

SP - 150

EP - 163

JO - European Competition and Regulatory Law Review

JF - European Competition and Regulatory Law Review

IS - 2

ER -